After complete resection, patients with stage II–III NSCLC (AJCC 8th TNM stage) without EGFR mutations or ALK rearrangements will be regularly monitored for the presence of MRD via the analysis of circulating tumor DNA levels in plasma samples. This evidence concerns the gene EGFR and non-small cell lung carcinoma.